Lower expression of CYP2A6 and CYP2D6, involved in the metabolism of tamoxifen, tegafur and CPA [123,124] may result in inefficient metabolism/activation of these agents which may affect survival of breast cancer patients as demonstrated in the current study. This evidence concerns the gene CYP2A6 and breast cancer.